Alere filed suit against Abbott Laboratories, claiming the medical device maker failed to get US antitrust clearance for the $5.8 billion merger underway between the two, potentially scuttling the controversial deal.
Abbott failed to “promptly secure antitrust approvals and other regulatory requirements,” Alere said in a filing in Delaware Chancery Court. The suit was filed under seal late Thursday and details weredisclosed in a filing on Friday.
Abbott has tried to get out of the agreement, offering to pay $30 million to $50 million of Alere’s legal costs. That offer was immediately rejected by Alere’s board earlier this year.
Full Content: Chicago Business
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI